NCT04714983View on ClinicalTrials.gov

DNX-2440 for Resectable Colorectal Liver Metastasis

PHASE1SuspendedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Liver MetastasesLiver Metastasis Colon CancerColorectal CancerBreast CancerGastric CancerPeriampullary CancerMelanomaRenal Cell CancerSarcomaSquamous Cell CarcinomaGastrointestinal Stromal Tumors
Interventions
BIOLOGICAL

DNX-2440

DNX-2440 is a replication competent oncolytic adenovirus expressing human OX40 ligand.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa

Sponsors

Lead Sponsor

DNAtrix, Inc.
All Listed Sponsors
collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

DNAtrix, Inc.

INDUSTRY

NCT04714983 - DNX-2440 for Resectable Colorectal Liver Metastasis | Biotech Hunter | Biotech Hunter